• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Population pharmacokinetics of racemic warfarin in adult patients.

作者信息

Mungall D R, Ludden T M, Marshall J, Hawkins D W, Talbert R L, Crawford M H

出版信息

J Pharmacokinet Biopharm. 1985 Jun;13(3):213-27. doi: 10.1007/BF01065653.

DOI:10.1007/BF01065653
PMID:3841364
Abstract

The population pharmacokinetics of racemic warfarin was evaluated using 613 measured warfarin plasma concentrations from 32 adult hospitalized patients and 131 adult outpatients. Warfarin concentrations were measured in duplicate using a high-performance liquid chromatographic procedure. The pharmacokinetic model used was a one-compartment open model with first-order absorption (absorption rate constant set equal to 47 day-1) and first-order elimination. The extent of availability was assumed to be one. A linear regression model was used to evaluate the influence of various demographic factors on warfarin oral clearance. Age appeared to be an important determinant of warfarin clearance in this adult population. There was about a 1%/year decrease in oral clearance over the age range of 20-70 years. Smoking appeared to result in a 10% increase in warfarin clearance, while coadministration of the inducers phenytoin or phenobarbital yielded about a 30% increase in clearance. This study has yielded a predictive model that, when combined with appropriate pharmacological response data, may be useful in the design and adjustment of warfarin regimens.

摘要

相似文献

1
Population pharmacokinetics of racemic warfarin in adult patients.
J Pharmacokinet Biopharm. 1985 Jun;13(3):213-27. doi: 10.1007/BF01065653.
2
Interaction of secobarbital with warfarin pseudoracemates.司可巴比妥与华法林假外消旋体的相互作用。
Clin Pharmacol Ther. 1980 Aug;28(2):187-95. doi: 10.1038/clpt.1980.149.
3
Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.日本儿童华法林对映体的药代动力学和药效学的发育变化。
Clin Pharmacol Ther. 2000 Nov;68(5):541-55. doi: 10.1067/mcp.2000.110977.
4
Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.依诺沙星与华法林的相互作用:药代动力学和立体化学方面。
Clin Pharmacol Ther. 1987 Jul;42(1):33-41. doi: 10.1038/clpt.1987.104.
5
Warfarin pharmacokinetics in the horse.
Am J Vet Res. 1983 Jul;44(7):1192-6.
6
Comparative pharmacokinetics of coumarin anticoagulants XXXV: Examination of possible pharmacokinetic interaction between (R)-(+)- and (S)-(--)-warfarin in humans.香豆素类抗凝剂的比较药代动力学XXXV:人体内(R)-(+)-和(S)-(-)-华法林之间可能的药代动力学相互作用研究
J Pharm Sci. 1978 Jun;67(6):867-8. doi: 10.1002/jps.2600670640.
7
Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations.华法林对映体的药代动力学:寻找个体内相关性。
Clin Pharmacol Ther. 1978 Feb;23(2):212-7. doi: 10.1002/cpt1978232212.
8
Kinetics of R andS warfarin enantiomers.R和S华法林对映体的动力学
Clin Pharmacol Ther. 1980 Jul;28(1):99-105. doi: 10.1038/clpt.1980.137.
9
Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans.胺碘酮与消旋华法林及其分离对映体在人体内的相互作用。
Clin Pharmacol Ther. 1987 Sep;42(3):290-4. doi: 10.1038/clpt.1987.149.
10
Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man.香豆素类抗凝剂的比较药代动力学L:大鼠体内S-华法林的生理模型及人体中药理学靶点介导的华法林处置
J Pharm Sci. 2003 May;92(5):985-94. doi: 10.1002/jps.10345.

引用本文的文献

1
Should Cytochrome P450 Inducers be Used to Accelerate Clearance of Brodifacoum from Poisoned Patients?细胞色素 P450 诱导剂是否可用于加速中毒患者体内溴鼠灵的清除?
Drugs R D. 2019 Mar;19(1):67-71. doi: 10.1007/s40268-019-0261-4.
2
Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin.成人年龄对(R)-和(S)-华法林总清除率、游离清除率和蛋白结合率的影响。
Br J Clin Pharmacol. 2012 Nov;74(5):797-805. doi: 10.1111/j.1365-2125.2012.04259.x.
3
Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing.

本文引用的文献

1
Metabolism of drugs in subjects with Laennec's cirrhosis.Laennec 肝硬化患者的药物代谢
Med Exp Int J Exp Med. 1959;1:290-2. doi: 10.1159/000134806.
2
Comparison of methods for estimating digoxin dosing regimens.地高辛给药方案估算方法的比较。
Am J Hosp Pharm. 1981 Jan;38(1):69-73.
3
Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.药代动力学的贝叶斯个体化:简单实现及与非贝叶斯方法的比较。
验证和比较基于药物遗传学的华法林剂量算法在药物遗传学检测中的应用。
J Mol Diagn. 2010 May;12(3):283-91. doi: 10.2353/jmoldx.2010.090110. Epub 2010 Mar 12.
4
Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients.重组凝血因子VIII:C(ReFacto)在成人HIV阴性和HIV阳性血友病患者中的群体药代动力学。
Eur J Clin Pharmacol. 2009 Nov;65(11):1121-30. doi: 10.1007/s00228-009-0699-3. Epub 2009 Jul 30.
5
Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.奈必卡朋对健康受试者华法林药代动力学和药效学的影响。
Eur J Clin Pharmacol. 2008 Oct;64(10):961-6. doi: 10.1007/s00228-008-0534-2. Epub 2008 Aug 6.
6
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.骨科患者华法林起始治疗的药物遗传学方案与临床方案的实验室及临床结果
J Thromb Haemost. 2008 Oct;6(10):1655-62. doi: 10.1111/j.1538-7836.2008.03095.x. Epub 2008 Jul 24.
7
Genetic-based dosing in orthopedic patients beginning warfarin therapy.开始华法林治疗的骨科患者基于基因的剂量确定。
Blood. 2007 Sep 1;110(5):1511-5. doi: 10.1182/blood-2007-01-069609. Epub 2007 Mar 26.
8
Pharmacogenetics and anticoagulant therapy.
J Thromb Thrombolysis. 2003 Aug-Oct;16(1-2):73-8. doi: 10.1023/B:THRO.0000014598.24114.62.
9
Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.采用非参数群体方法检测药物-药物药效学相互作用。设计和个体间变异性的影响。
J Pharmacokinet Biopharm. 1999 Oct;27(5):531-54. doi: 10.1023/a:1023290530853.
10
Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.华法林治疗起始阶段国际标准化比值及维持剂量的预测
Br J Clin Pharmacol. 1999 Jul;48(1):63-70. doi: 10.1046/j.1365-2125.1999.00967.x.
J Pharm Sci. 1982 Dec;71(12):1344-8. doi: 10.1002/jps.2600711209.
4
Estimating population kinetics.估计群体动力学。
Crit Rev Biomed Eng. 1982;8(3):195-222.
5
Population pharmacokinetic data and parameter estimation based on their first two statistical moments.基于前两个统计矩的群体药代动力学数据和参数估计。
Drug Metab Rev. 1984;15(1-2):173-93. doi: 10.3109/03602538409015064.
6
Steady-state pharmacokinetics of phenytoin from routinely collected patient data.
Clin Pharmacokinet. 1983 Jul-Aug;8(4):355-64. doi: 10.2165/00003088-198308040-00006.
7
Plasma protein binding of warfarin: methodological considerations.华法林的血浆蛋白结合:方法学考量
J Pharm Sci. 1984 Jul;73(7):1000-1. doi: 10.1002/jps.2600730738.
8
Clinical implications of enzyme induction.酶诱导的临床意义。
Ann N Y Acad Sci. 1971 Jul 6;179:421-31. doi: 10.1111/j.1749-6632.1971.tb46919.x.
9
In vivo and in vitro availability of commercial warfarin tablets.市售华法林片剂的体内和体外生物利用度
J Pharm Sci. 1971 May;60(5):666-77. doi: 10.1002/jps.2600600503.
10
Smoking and warfarin dosage.吸烟与华法林剂量
N Engl J Med. 1972 Nov 30;287(22):1153-4.